Doug Levinson

Doug Levinson is the partner of Flagship Ventures and he joined Flagship in 2006， bringing over 15 years of experience in the biotech industry to the VentureLabs unit. Prior to Flagship， Doug was with TransForm Pharmaceuticals （acquired by Johnson & Johnson） since 2000 as part of its scientific founding-team joining Professors Bob Langer and Michael Cima of MIT. Most recently， he was Vice President of Emerging Science and Technology and led the design， development and implementation of TransForm's basic technology platforms and business model. TransForm was acquired by Johnson & Johnson for $230 million in 2005.

Prior to TransForm， Doug was with Millennium Pharmaceuticals， which he joined as a founding scientific team member. At Millennium for seven years， Doug was responsible for establishing the company's early scientific program in Immunology/Inflammation， which he grew to the largest research effort at Millennium with a staff of 170 researchers. Before joining Millennium， he was with Creative Biomolecules where he was responsible for the generation of synthetic single-chain antibody molecules.

Doug holds a Ph.D. in Genetics from Harvard University and a B.S. cum laude in Molecular Biology from the University of Massachusetts. He has authored numerous patents in the field of high throughput platform technologies and molecular genetics and has published extensively in scientific journals.

Doug has been a co-founder of two Flagship VentureLabs companies: T2 Biosystems and Seventh Sense Biosystems. Doug currently serves as CEO of Seventh Sense and was the Founding CEO of T2 Biosystems. He also actively participates in the conception and launch of new companies from the VentureLabs.